Actively Recruiting
Phase II Study of Cretostimogene for Patients 18 and Older With High-risk Non-Muscle Invasive Bladder Cancer Not Responding to BCG Treatment
Led by Lepu Biopharma Co., Ltd. · Updated on 2026-04-23
16
Participants Needed
14
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the efficacy and safety of Cretostimogene in patients with high-risk non-muscle invasive bladder cancer NMIBC that has not responded to Bacillus-Calmette-Guerin BCG treatment. It focuses on patients who have carcinoma in situ CIS, with or without Ta or T1 papillary tumors. This open-label, phase II study is designed to assess outcomes in this specific patient group who have previously failed BCG therapy. Participants receive Cretostimogene administered directly into the bladder intravesically following bladder washes with 5% n-dodecyl-B-D-maltoside DDM and normal saline. The treatment is given weekly according to a specific protocol schedule. The study has a single treatment arm enrolling patients with CIS and possible concomitant high-grade Ta or T1 papillary disease. During the study, patients will undergo regular evaluations including cystoscopies, urine cytology, urograms, biopsies, and tumor resections as needed. Researchers will monitor complete response rates, duration of response, recurrence-free survival, progression-free survival, overall survival, and safety over a period of 36 months. Participants are expected to comply with all study procedures, and safety monitoring includes assessing adverse events throughout the trial.
CONDITIONS
Brief Title
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Research Team
P
Program Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here